TickerHumSide-by-side comparison
AbbVie vs Amgen
As of Nov 11, 2026, P/E is 50.4x for AbbVie vs 26.9x for Amgen; P/S is 7.8x for AbbVie vs 6.4x for Amgen; revenue growth is 10.7% for AbbVie vs 8.2% for Amgen; operating margin is 32.2% for AbbVie vs 32.4% for Amgen.
What stands out
- Amgen is cheaper on earnings: 26.9x P/E vs 50.4x for AbbVie.
Key metrics
| Metric | ABBV | AMGN |
|---|---|---|
| Price | $292.77 | $463.47 |
| Market cap | $517.5B | $250.69B |
| P/E | 50.4x (#2) | 26.9x (#1) |
| P/S | 7.8x (#2) | 6.4x (#1) |
| Revenue growth | 10.7% (#1) | 8.2% (#2) |
| Operating margin | 32.2% (#2) | 32.4% (#1) |
| Net margin | 15.7% (#2) | 24.1% (#1) |
| Debt / equity | — | 3.60 (#1) |
| 1-year return | +25.5% (#2) | +37.8% (#1) |
| Research score | 62/100 (#2) | 68/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Amgen Inc. (AMGN) — Drug Manufacturers—General